Bavarian Nordic Secures Massive USD 1.5 Billion Order from US for Smallpox Vaccine

A Strategic Stockpile Replenishment

Bavarian Nordic, a leading biotech company, has announced a groundbreaking contract with the United States government worth a staggering USD 1.568 billion. This substantial order is a testament to the urgent need to replenish strategic stockpiles of smallpox vaccines.

Expanding Production Capacity

The contract will empower Bavarian Nordic to increase production capacity for its highly effective smallpox vaccine. This will ensure a robust supply of this life-saving vaccine, mitigating the risks associated with potential outbreaks in the future.